Clinical Trials Directory

Trials / Completed

CompletedNCT05572138

Body Impedance Analysis to Detect ICUAW

Body Impedance Analysis to Detect Muscle Strength Associated With ICU Acquired Weakness

Status
Completed
Phase
Study type
Observational
Enrollment
62 (actual)
Sponsor
Charite University, Berlin, Germany · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to detect a value of muscle and organ mass measured by body impedance analysis and its correlation with the Medical Research Council (MRC) score. An MRC score ≤ 48 is defined as a diagnosis of ICU acquired weakness. The correlation of the values detected by BIA and their transfer to an MRC Score ≤ 48 will be investigated. The knowledge gained will be used for early detection of ICUAW in order to reduce the consequences of the same.

Detailed description

Intensive Care Unit Acquired Weakness (ICUAW) describes the clinically diagnosed manifestation of neuromuscular organ dysfunction. It develops in approximately 40% of all ICU patients, which corresponds to at least 1.2 million patients annually in Germany. All these patients face a wide spectrum of sequelae and increased mortality up to 5 years after ICU discharge. A characteristic pathophysiological phenomenon is early severe muscle atrophy, which is as high as 17% in the first days after ICU admission. ICUAW is currently diagnosed by the MRC score, which is assessed by the sum of manual muscle strength test results in 12 muscle groups (sum score). Manual muscle testing (MMT) is not possible during the early phase in critical illness in most patients due to coma, delirium, and/or injury. In addition, there is a possible discrepancy by different observers. As a result, early detection of ICUAW may be inadequate in most patients and unreliable during critical illness. Measurement by BIA is reproducible, so differences in measurement can be attributed to changes in clinical condition. Body impedance analysis thus demonstrates a means of objective measurement. Thus, the study aims to counteract the long-term consequences of ICUAW through early detection of ICUAW by allowing countermeasures to be taken earlier.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTBody Impedance AnalysisBody Impedance Analysis

Timeline

Start date
2023-02-08
Primary completion
2024-01-28
Completion
2024-01-28
First posted
2022-10-07
Last updated
2024-02-06

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT05572138. Inclusion in this directory is not an endorsement.